Ani Pharmaceuticals (ANIP) Profit After Tax (2010 - 2026)

Ani Pharmaceuticals has disclosed Profit After Tax across 17 years of filings, most recently posting $24.7 million for Q2 2026.

• In Q2 2026, Profit After Tax rose 189.05% year-over-year to $24.7 million; the TTM figure through Jun 2026 stood at $108.3 million (up 1160.61% YoY), while the FY2025 annual figure was $78.3 million, up 522.94% from the prior year.
• Profit After Tax came in at $24.7 million for Q2 2026 at Ani Pharmaceuticals, down from $29.5 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $29.5 million in Q1 2026 to a low of -$24.2 million in Q3 2024.
• Average Profit After Tax over 5 years is $4.7 million, with a median of $3.8 million recorded in 2023.
• Year-over-year, Profit After Tax slumped 23977.91% in 2022 and jumped 1165.25% in 2024.
• Over 5 years, Profit After Tax stood at -$4.2 million in 2022, then jumped by 127.22% to $1.2 million in 2023, then plunged by 989.7% to -$10.3 million in 2024, then surged by 367.52% to $27.5 million in 2025, then declined by 10.11% to $24.7 million in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were $24.7 million in Q2 2026, $29.5 million in Q1 2026, and $27.5 million in Q4 2025.